Market capitalization | $12.21m |
Enterprise Value | $-6.98m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.64 |
EV/Sales (TTM) EV/Sales | -1.06 |
P/S ratio (TTM) P/S ratio | 1.85 |
P/B ratio (TTM) P/B ratio | 0.66 |
Revenue growth (TTM) Revenue growth | -3.23% |
Revenue (TTM) Revenue | $6.59m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
2 Analysts have issued a Marker Therapeutics, Inc. forecast:
2 Analysts have issued a Marker Therapeutics, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 6.59 6.59 |
3%
3%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -11 -11 |
17%
17%
|
EBIT (Operating Income) EBIT | -11 -11 |
23%
23%
|
Net Profit | -11 -11 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Head office | United States |
CEO | Juan Vera |
Employees | 5 |
Founded | 1991 |
Website | www.markertherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.